Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (638)	5/2/1998 11:17:00 PM
From: Binder	Read Replies (2) \| Respond to of 2887

Jeffrey, For the benefit of anyone coming here from a Hot Topics link who does not have previous knowledge of American Biomed, I would like to post the following, which was taken directly from their website: American BioMed, Inc. presents a unique set of circumstances that equate into an awesome investment opportunity. It is a company that is coming out of R & D and is just beginning to fully commercialize its various product lines. These products include but are not limited to patented and unique products such as stents, catheters and the OmniCathr, ABMI's atherectomy catheter. Stents are the new wave in cardiology. These small devices use self-expanding nitinol that helps keep blood vessels open after an angioplasty has been performed. Its stent delivery system does not infringe on Johnson & Johnson's (NYSE: JNJ) patented balloon delivery system. ABMI is also positioning itself as the premier provider of all-silicone based catheters. Their nine FDA approved catheters are silicone based and have broad uses. The OmniCathr is an atherectomy device which actually removes plaque buildup from blood vessels. It vacuums and filters distally preventing embolisms and thereby helps return blood flow back to normal levels. There is added valuation due to the recent acquisition of InStent, Inc (NASDAQ: ININ) for $214.6 million by Medtronic, Inc. (NYSE: MDT), due to the similarity of the stent delivery systems of InStent and American BioMed. The OmniCathr is currently being marketed in Europe and is in stage two of the FDA approval process and is about to submit its 510-K filing in order to speed up the process which will fully commercialize the unit in the United States. This is a company that is destined for hockey stick sales growth and could be a takeover candidate. Now the Company is positioned to start a further commercialization of their products by increasing market penetration and concentrating on the vascular area where they have many product lines. This sales effort will be headed up by Art Przybyl who has an impressive medical sales career. The Company will look to divest themselves of patented technologies that are outside of this arena. This will further define focus and raise cash in the process. The Company was founded in 1984 with an IPO in 1991. Usually a poorly managed IPO does not equate into success years down the road. In this case it does. At the time of the IPO, scientists controlled the direction of American BioMed. These scientists were more interested in the esoteric principles of new designs that varied across different medical methodologies with no focus on a single market segment. Because of this, ABMI holds a cornucopia of patents (26 granted or pending) on different medical devices but did not have any real revenues. The scientists were more interested in creating products rather than delivering them to the market-place. This corporate culture was slowly eating away at ABMI's market capitalization and driving the Company towards bankruptcy. Under the new direction of Steven Rash, the management is taking off their lab coats and turning them in for business suits in order to drive revenues through the door. KEY POINTS: Major companies in the medical community are aggressively pursuing companies with advanced technologies for acquisition, strategic alliances and joint ventuers. Experienced Management (Industry and turn-around specialists). Scientific Advisory Board (Experts in vascular and regulatory fields). Nine FDA approved catheters. Over 25 patented devices competing in industries with combined markets estimated at over $10-billion annually. The Company is looking to divest itself of other "less profitable" technologies and converting these into cash. Extreme focus on top-line growth this year. A noteworthy point in regards to American BioMed is that they have their own manufacturing facility in Irvine, California. It is unusual for a company this size to have such an advanced facility. The facility just passed a strict FDA inspection that had no 483 deficiencies. This is almost unheard of within the industry and is a testament to both Robert L. Poss's (Director of Manufacturing) and Harold Fujimoto's (plant manager) attention to detail and strict controls in the manufacturing process within a world class production facility. ABMI is a very good company with unique products that are grabbing the attention of industry analysts. The Company has been contacted by and is currently corresponding with several major U.S. and international medical companies. Management has undertaken efforts to identify healthcare companies with similar technologies to its own or companies that are seeking new proprietary products to strengthen their existing market position. This strategy is directed toward the formation of strategic alliances, joint venture arrangements and licensing and distribution agreements. MARKET CONDITIONS Over 65 million Americans suffer from some form of coronary or peripheral vascular disease. This equates to a potential market for ABMI's products in the U.S. alone at one in four Americans. That is a large and exceedingly profitable market. Cardiovascular disease is both progressive and degenerative, and is characterized by a buildup of fatty materials (plaque) within the inner lining of the arterial blood vessels. This buildup results in an obstruction (stenosis) that reduces blood flow through the arteries and may eventually lead to total blockage, causing tissue damage and even death. The plaque forms in varying degrees which reduces the elastic nature of the vessel and therefore compromises the ability to efficiently pump blood to vital organs. Despite significant advances in product technologies, the disease continues to be the leading cause of death in the United States. New, less invasive technologies are coming to the forefront of the vascular field. As technology evolves so do the treatment options for people with heart disease. Since the 1970's balloon angioplasty has been technologies answer to aiding doctors in the fight against heart disease. The latter half of the 1990's is heralding in a new age of less invasive technologies to arm the medical community in the battle against heart disease. ABMI has armed itself with a battery of products to effectively compete in these markets. Its primary focus is to penetrate and capture significant market share in this $2.4 billion and growing market. The Company will further enhance this direction by aggressively utilizing its resources on its core technologies. ABMI believes it can capture market share by providing superior products using their patented technologies and systems that focus on the vascular arena. This area includes the OmniCathr, catheters, stents and stent delivery systems. The market is growing at 35 - 50% per year as baby boomers continue to age. Go ABMI! :-) Binder

To: Jeffrey L. Henken who wrote (638)	5/2/1998 11:32:00 PM
From: Bron-y-aur	Read Replies (2) \| Respond to of 2887

jeff followed you over here from newbridge thread. ambi looks very interesting. had a quick look at last earnings release and albeit the company is in the transition stage between r&d and commercialization, am wondering about working capital/financing. can you fill me in on where they are at as cash balance was low per mar 31 statement. in this context,do you know/have thoughts about whether the company's management plans to go it alone, or if they are/would be actively seeking a partner/buyout. any other current/going forward info appreciated including boutiques who may be recommending stock as a spec buy, research reports if any etc. thanks sam g